Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 7Sarcoma 3Small Cell Lung Carcinoma 2Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1cobimetinib 1TAK-981 1Ipilimumab 1Doxorubicin 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced or Metastatic Solid Tumors × surufatinib × Clear all
NCT04427774 2021-07-20

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡